NEW YORK, September 16, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Macrocure Ltd. (NASDAQ: MCUR). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/reports?keyword=MCUR

Highlights from our MCUR Report include: 


        
        - Second Quarter and First Half Results - On August 04, 2015, Macrocure Ltd., a
          clinical-stage biotechnology company announced its financial results for the second
          quarter and first half of the year along with corporate updates. For the second
          quarter, the Company reported a net loss of $6.7 million or a loss of $0.37 per basic
          and diluted share compared with a net loss of $4.4 million or loss of $0.59 per basic
          and diluted share in Q2 2014. For the first half of the year the Company posted a net
          loss of $13.6 million or a loss of $0.74 per basic and diluted share versus a net loss
          of $7.8 million or a loss of $1.05 per basic and diluted share in the corresponding
          prior year period.



        
        - An Update on R& D Expenses - Research and development expenses for the second
          quarter of 2015 were $4.8 million, compared with $3.2 million for the second quarter
          of 2014. Research and development expenses for H1 2015 stood at $10.1 million,
          compared with $5.9 million for the comparable period in 2014.  As per the Company,
          this increase was primarily due to increases in ongoing clinical trial expenses for
          its DFU and VLU Phase III clinical studies.



        
        - Guidance - In its results announcement the Company reiterated that expected cash
          used for its ongoing operating activities in 2015 will be in the range of $21
          million-$25 million which would be inclusive of the $11.5 million of cash already
          expended in the first half of 2015, reflecting anticipated expenditures to complete
          its current Phase III clinical trials in process this year. The Company added that the
          range however, excludes approximately $4 million in potential capital expenditures in
          2015 primarily related to the Company's anticipated new U.S. manufacturing facility.



        
        - Management Note and Corporate Update - Nissim Mashiach, President and CEO of the
          Company said that in this quarter the Company advanced its two pivotal Phase III
          clinical trials of its lead product candidate CureXcell. He added that the Company
          remained on track to receive futility analysis results in the VLU trial in August and
          report top-line study results in the first half of 2016. He then moved on to say that
          the Company was making progress towards the completion of its DFU trial, which he said
          remains on track to report top-line results in October 2015.

To find out how this influences our rating on Macrocure Ltd. read the full report in its entirety here: http://www.aciassociation.com/reports?keyword=MCUR

--

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  

NO WARRANTY 

ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com